Abstract
Protective immune responses to dengue virus infection and vaccines: perspectives from the field to the bench.
Highlights
A longitudinal study on human immune responses to wild-type dengue virus (DENV) infection describes how heterotypic immunity modulates disease, including evidence that cellular immunity contributes to protection [8]
Studies on humans and animal models, summarized by Petitdemange et al [9], find that antibody-dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cells contribute to controlling early-stage viral infections
Monkeys inoculated with tetravalent Sanofi and Takeda live-attenuated chimeric vaccines revealed the same dominance of DENV 4 and DENV 2-driven immune responses and protection observed in humans, respectively
Summary
A longitudinal study on human immune responses to wild-type DENV infection describes how heterotypic immunity modulates disease, including evidence that cellular immunity contributes to protection [8]. Weiskopf and Sette show that CD8+ T cells contribute to protection against disease with second DENV infections by targeting epitopes on non-structural antigens [8]. In the Sanofi tetravalent chimeric vaccine, this T cell contribution may be missing as DENV non-structural proteins are not present in the vaccine, replaced by those of yellow fever [1,2,3].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
